Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
129 stopped studies mapped to Esophageal and Gastroesophageal Junction Carcinoma and descendants · 95% state a reason
Over the 129 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05056805 | An Exercise and Nutrition Monitoring Intervention (Pt Pal) for the Improvement of… | N/A | withdrawn | Sep 27, 2021 | M.D. Anderson Cancer Center | No participants enrolled. | Enrollment / accrual |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT05780736 | A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or…(PROSPECT-ESO) | — | terminated | Mar 23, 2023 | Bristol-Myers Squibb | A decision was made to terminate the study due to expected timelines associated with start-up,… | Enrollment / accrual |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer… | Phase 2 | terminated | Jan 16, 2024 | LianBio LLC | Business Reason | Sponsor / business decision |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04604132 | Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in…(FIDES-03) | Phase 1 / Phase 2 | terminated | Oct 27, 2020 | Basilea Pharmaceutica | Terminated prematurely for administrative reasons not related to patient safety. | Safety / toxicity |
| NCT05687617 | Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases for… | Phase 2 | terminated | Jan 18, 2023 | Laval University | Recruitment lower than expected and negative results. | Enrollment / accrual |
| NCT04682431 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With… | Phase 1 | terminated | Dec 23, 2020 | Ikena Oncology | Sponsor business decision. | Sponsor / business decision |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine… | Phase 1 | withdrawn | Oct 26, 2020 | QuantumLeap Healthcare Collaborative | Study withdrawn as scientific interest in pursuing the SYD985+Paclitaxel combination has diminished. | Other (stated, no rule matched) |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or… | Phase 2 | terminated | Mar 3, 2011 | University of Nebraska | Drug manufacturer - Amgen requested study stop, per DSMB observation in POWER trial | Drug supply |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | N/A | terminated | Jul 26, 2021 | Erasme University Hospital | Urgent Medical Device Product (ORISE Gel Submucosal Liftiong Agent) Removal by sponsor | Other (stated, no rule matched) |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic…(REGIRI) | Phase 1 / Phase 2 | terminated | Oct 26, 2018 | UNICANCER | Unfavorable benefit-risk balance in the experimental arm following the IDMC for intermediate… | Safety / toxicity |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03233724 | Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated… | Phase 1 / Phase 2 | terminated | Jul 31, 2017 | National Cancer Institute (NCI) | Study terminated due to drug supply issues. | Drug supply |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian… | Phase 3 | terminated | Jan 12, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | N/A | terminated | Aug 7, 2017 | Mayo Clinic | Difficulty obtaining investigational product and study support. | Other (stated, no rule matched) |
| NCT03251417 | Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal… | Phase 2 | terminated | Aug 16, 2017 | Peking University | Because PD-1 antibodies had been proved to be a standard second-line treatment in esophageal… | Other (stated, no rule matched) |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+… | Phase 2 | terminated | Aug 12, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | — | terminated | Nov 24, 2020 | Mayo Clinic | could not collect adequate samples | Other (stated, no rule matched) |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT05091528 | A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies… | Phase 1 / Phase 2 | terminated | Oct 25, 2021 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT00573131 | Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in… | Phase 2 | terminated | Dec 13, 2007 | Boston Scientific Corporation | OncoGel did not show any impact on overall tumor response | Other (stated, no rule matched) |
| NCT04625543 | Neoadjuvant Immunotherapy to ESCC | Phase 2 | withdrawn | Nov 12, 2020 | Qilu Hospital of Shandong University | insufficient money | Other (stated, no rule matched) |
| NCT03707028 | A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With… | Phase 1 / Phase 2 | terminated | Oct 16, 2018 | Elevar Therapeutics | Terminated after completion of Part 1 due to a change in research plan. | Other (stated, no rule matched) |
| NCT03278626 | Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | terminated | Sep 11, 2017 | NYU Langone Health | The study was stopped earlier than anticipated due to slow accrual | Enrollment / accrual |
| NCT03735290 | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors…(ILIAD) | Phase 1 | terminated | Nov 8, 2018 | Mendus | Decision made not to move to Phase 2 | Other (stated, no rule matched) |
| NCT03592407 | Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III… | Phase 2 | withdrawn | Jul 19, 2018 | City of Hope Medical Center | Safety concerns | Safety / toxicity |
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | N/A | withdrawn | Aug 11, 2021 | Fujian Cancer Hospital | We could not get the IRB approval. | Other (stated, no rule matched) |
| NCT04099277 | A Study of LY3435151 in Participants With Solid Tumors | Phase 1 | terminated | Sep 23, 2019 | Eli Lilly and Company | Study terminated due to strategic business decision by Eli Lilly and Company. | Sponsor / business decision |
| NCT00003487 | Antineoplaston Therapy in Treating Patients With Cancer of the Esophagus | Phase 2 | terminated | Jan 27, 2003 | Burzynski Research Institute | Slow accrual | Enrollment / accrual |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in… | Phase 1 / Phase 2 | withdrawn | Jul 9, 2020 | NKGen Biotech, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable… | Phase 2 / Phase 3 | withdrawn | Oct 23, 2014 | Peking University | Because there are questions about adjuvant radiotherapy in this study, the clinical trial is under… | Other (stated, no rule matched) |
| NCT04084158 | A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced… | Phase 2 | suspended | Sep 10, 2019 | Zhejiang Cancer Hospital | combination arm delevelped significant poor prognosis | Other (stated, no rule matched) |
| NCT00064259 | A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal… | Phase 1 / Phase 2 | terminated | Jul 9, 2003 | National Cancer Institute (NCI) | Discontinued development of G3139 (oblimersen) | Other (stated, no rule matched) |
| NCT02862535 | Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in… | Phase 1 | terminated | Aug 11, 2016 | Gilead Sciences | Study was terminated due to sponsor's decision to not pursue further development of andecaliximab… | Sponsor / business decision |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03511222 | Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors | Phase 1 | terminated | Apr 27, 2018 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil… | Phase 2 | terminated | Dec 23, 2013 | Nang Kuang Pharmaceutical Co., Ltd. | not stated | Not stated |
| NCT03206125 | NCI UNC Project ESCC | — | terminated | Jul 2, 2017 | National Cancer Institute (NCI) | determined not to be human subjects research | Other (stated, no rule matched) |
| NCT03739801 | MM-398 and Ramucirumab in Treating Patients With Gastric Cancer or Gastroesophageal… | Phase 1 / Phase 2 | withdrawn | Nov 14, 2018 | University of Southern California | PI left | Investigator |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer… | Phase 2 | terminated | Feb 14, 2014 | Mayo Clinic | Poor accrual | Enrollment / accrual |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 2, 2016 | Seagen Inc. | Due to overall benefit/risk profile | Other (stated, no rule matched) |
| NCT01498757 | Genome-wide Association Study | — | withdrawn | Dec 23, 2011 | Samsung Medical Center | Registration poor | Other (stated, no rule matched) |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type…(E-DIS) | Phase 2 | terminated | Nov 25, 2010 | Centre Oscar Lambret | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Oct 26, 2024source: clinicaltrials